Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines

Importance of the field: Many vaccines require the use of an Adjuvant to achieve immunity. So far, few adjuvants have advanced successfully through clinical trials to become part of licensed vaccines. Vaxfectin® (Vical, CA, USA) represents a next-generation Adjuvant with promise as a platform technology, showing utility with both plasmid DNA (pDNA) and protein-based vaccines.

Areas covered in this review: This review describes the chemical, physical, preclinical and clinical development of Vaxfectin for pDNA-based vaccines. Also included is the preclinical development of Vaxfectin-adjuvanted protein- and peptide-based vaccines.

What the reader will gain: The reader will gain knowledge of vaccine Adjuvant development from bench to bedside.

Take home message: Vaxfectin has effectively boosted the immune response against a range of pDNA-expressed pathogenic antigens in preclinical models extending from rodents to non-human primates. In the clinic, Vaxfectin-adjuvanted pDNA-based H5N1 influenza vaccines have been shown to be well tolerated and to result in durable immune responses within the predicted protective range reported for protein-based vaccines.